Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.59 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14985490 | 0.82 | IDO1 (0.50) | L3MBTL1ALKIDO1METAP2NPC1 | |
| SCHEMBL427627 | 0.82 | L3MBTL1 (1.00) | L3MBTL1ALKNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4116250 | 0.81 | L3MBTL1 (0.65) | L3MBTL1ALKIDO1NPC1RAB9A | |
| SCHEMBL16115554 | 0.81 | NPC1 (0.66) | L3MBTL1ALKIDO1METAP2NPC1 | |
| SCHEMBL17279800 | 0.81 | RAB9A (0.56) | L3MBTL1IDO1METAP2NPC1RAB9A | |
| SCHEMBL16682100 | 0.81 | L3MBTL1 (0.65) | L3MBTL1ALKMETAP2NPC1RAB9A | |
| SCHEMBL14726245 | 0.81 | IDO1 (0.53) | L3MBTL1ALKIDO1METAP2NPC1 | |
| SCHEMBL23773640 | 0.81 | IDO1 (0.49) | L3MBTL1ALKIDO1METAP2NPC1 | |
| SCHEMBL15006259 | 0.80 | RAB9A (0.70) | L3MBTL1IDO1METAP2NPC1RAB9A | |
| SCHEMBL29335678 | 0.80 | RAB9A (0.55) | L3MBTL1IDO1METAP2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| EP-4103281-A1 | PIKFYVE KINASE INHIBITORS | Acurastem Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021163727-A1 | PIKFYVE KINASE INHIBITORS | AcuraStem Incorporated (US) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021163727-A1 | PIKFYVE KINASE INHIBITORS | AcuraStem Incorporated (US) | 2021-08-19 | — | — | WO | disclosed |
| US-20180133221-A1 | ADMINISTRATION OF UBIQUITIN-ACTIVATING ENZYME INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | MILLENNIUM PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20170333434-A1 | ADMINISTRATION OF UBIQUITIN-ACTIVATING ENZYME INHIBITOR AND RADIATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | PIKFYVE, PIP5K1B, PIP5K1C | L3MBTL1 2305/4885ALK 894/4885IDO1 3172/4885 |
| US-20170333434-A1 | ADMINISTRATION OF UBIQUITIN-ACTIVATING ENZYME INHIBITOR AND RADIATION | UBE2E1, UBA1, USP1 | L3MBTL1 2609/4885ALK 4363/4885IDO1 809/4885 |
| US-20180133221-A1 | ADMINISTRATION OF UBIQUITIN-ACTIVATING ENZYME INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | USP1, UBA1, UBE2E1 | L3MBTL1 2663/4885ALK 4308/4885IDO1 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.